The therapy choice for BP-CML depends on several factors: de novo presentation or progression after CP-CML, immunophenotype, prior TKIs that the patient has been exposed to, the presence of ABL1 mutations and whether the patient is fit for intensive chemotherapy and allo-HSCT [20]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.